Loading viewer...
investor_presentation
Format: PDF investor_presentation
CNSX: IAN OTCQX: ITHUFOctober 2018 Driven to Lead CNSX: MPX OTCQX: MPXEF
OTCQX: ITHUFOctober 2018
OTCQX: MPXEF2Disclaimer
Cautionary Note Regarding Forward -Looking Information
This investor presentation dated October 18, 2018 contains certain “forward -looking information” or “forward -looking statements” as defined under applicable securities laws
(collectively, “forward -looking information”) that involve a number of risks and uncertainties. Forward -looking information incl udes all statements that are predictive in nature or depend
on future events or conditions. Forward -looking information can often be identified by forward -looking words such as “will”, “co uld”, “should”, “may”, “anticipates”, “believes”,
“expects”, “plans”, “intends”, “estimates”, “potential”, and similar expressions. Statements regarding the operations, busine ss,financial condition, priorities, ongoing objectives and
outlook of iAnthus Capital Holdings, Inc. (“ iAnthus ”), MPX Bioceutical Corporation (“ MPX ”), the combined company, and 2660528 Ontario Ltd., being the company resulting from the
spin-out of MPX’s non -U.S. businesses (“ MPX International ”) other than statements of historical fact, constitute forward -looking information.
Forward -looking information is not a guarantee of future performance and should not be unduly relied upon. Forward -looking infor mation reflects the analysis of the management of
the parties only as of the date hereof, and which by its nature involves numerous assumptions, inherent risks and uncertainti es,both general and specific, that contribute to the
possibility that the predictions and various future events will not occur. The parties do not undertake any obligation to re lease publicly the results of any revision to the forward -looking
information unless otherwise required by applicable law.
In addition to the information contained in the pro forma financial information, this presentation includes forward -looking information relating to:
othe arrangement agreement between the parties dated October 18, 2018 (the “ Arrangement Agreement ”) and the timing of approvals related thereto;
othe proposed acquisition of the MPX common shares by iAnthus, the issuance of the MPX International shares and the business, operation and financial performance and condition
of the combined company and MPX International following completion of the transaction contemplated in the Arrangement Agreeme nt (the “ Arrangement ”);
osynergies and financial impact of the Arrangement;
othe growth in the medical and adult -use cannabis industry; and
othe growth in the combined company’s market share,
and such is based on current expectations and beliefs concerning future developments and their potential effects on iAnthus, MPX , the combined company and MPX International.
Assumptions, including among other things, that the shareholders of MPX will approve the Arrangement, that all regulatory app rovals will be obtained, and that all of the conditions to
Preview truncated — download the full document for the complete content.
investor_presentation
28 Pages
Intellia Therapeutics